Peroxisome proliferators, which function as peroxisome proliferator-activated receptor ␣ (PPAR␣) agonists, induce peroxisomal, microsomal, and mitochondrial fatty acid oxidation enzymes, in conjunction with peroxisome proliferation, in liver cells. Sustained activation of PPAR␣ leads to the development of liver tumors in rats and mice. The assertion that synthetic PPAR␣ ligands pose negligible carcinogenic risk to humans is attributable, in part, to the failure to observe peroxisome proliferation in human hepatocytes. To explore the mechanism(s) of species-specific differences in response to PPAR␣ ligands, we determined the functional competency of human PPAR␣ in vivo and compared its potency with that of mouse PPAR␣. Recombinant adenovirus that expresses human or mouse PPAR␣ was produced and administered intravenously to PPAR␣-deficient mice. Human as well as mouse PPAR␣ fully restored the development of peroxisome proliferator-induced immediate pleiotropic responses, including peroxisome proliferation and enhanced expression of genes involved in lipid metabolism as well as nonperoxisomal genes, such as CD36, Ly-6D, Rbp7, monoglyceride lipase, pyruvate dehydrogenase kinase-4, and C3f, that have been identified recently to be up-regulated in livers with peroxisome proliferation. These studies establish that human PPAR␣ is functionally competent and is equally as dose-sensitive as mouse PPAR␣ in inducing peroxisome proliferation within the context of mouse liver environment and that it can heterodimerize with mouse retinoid X receptor, and this human PPAR␣-mouse retinoid X receptor chimeric heterodimer transcriptionally activates mouse PPAR␣ target genes in a manner qualitatively similar to that of mouse PPAR␣.
Peroxisomes, cytoplasmic organelles of about 0.5 m in diameter, participate in several important metabolic functions, including simple respiration characterized by H 2 O 2 production and H 2 O 2 degradation, ␤-oxidative chain shortening of long chain and very long chain fatty acids, metabolism of glyoxalate, degradation of uric acid, and synthesis of ether phospholipids, cholesterol, and bile acids (1) . A profound increase in the size and number of peroxisomes occurs in livers of rats and mice exposed to a broad spectrum of structurally diverse compounds of industrial, pharmaceutical, and agricultural importance designated as peroxisome proliferators (2) . These include certain phthalate ester plasticizers, herbicides, leukotriene D 4 receptor antagonists, and lipid-lowering drugs, such as clofibrate, ciprofibrate, fenofibrate, gemfibrozil, and Wy-14,643, among others (2, 3) . The induction of peroxisome proliferation is mediated by peroxisome proliferator-activated receptor ␣ (PPAR␣), 1 a member of the subfamily of ligand-dependent nuclear transcription factors that regulate the expression of genes associated with lipid metabolism and adipocyte differentiation (4 -6) . The PPAR subfamily consists of three isotypes (␣, ␤ or ␦, and ␥), which exhibit distinct patterns of tissue distribution and differ considerably in their ligand binding domains and specificities, attesting to the fact that they perform different functions in different cell types (4 -6) . PPARs contain a central cysteinerich zinc finger motif DNA binding domain that recognizes DNA sequence elements, designated peroxisome proliferator response elements (PPREs), containing direct repeats of the hexanucleotide sequence AGGTCA separated by one nucleotide present in the 5Ј-flanking region of target genes (4, 7) . PPARs heterodimerize with retinoid X receptor (RXR), a receptor for 9-cis-retinoic acid (7); the ligand-activated PPAR-RXR heterodimer binds the PPRE to transcriptionally activate target genes (4, 5, 7) . PPAR␣-dependent induction of peroxisome proliferation in liver is associated with concomitant transcriptional activation of genes encoding for the classical peroxisomal straight chain fatty acid ␤-oxidation system, microsomal cytochrome P450 CYP4A isoforms CYP4A1 and CYP4A3, and some of the genes involved in the mitochondrial ␤-oxidation among others (1, 8 -11) . Chronic induction of the morphological phenomenon of hepatic peroxisome proliferation as well as sustained activation of a variety of genes that contain PPREs in their promoters appear to play a role in the development of liver tumors in rodents exposed to synthetic and endogenous PPAR␣ ligands (2, 3, 12) . Mice lacking PPAR␣ (PPAR␣ Ϫ/Ϫ ) (13) and those lacking both PPAR␣ and AOX of the classical peroxisomal ␤-oxidation system (PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ ) (14, 15) are refractory to the induction of peroxisome proliferation and PPAR␣-regulated changes in gene expression in livers by synthetic as well as natural PPAR␣ ligands, indicating that the PPAR␣ isotype is solely responsible for the peroxisome proliferator-induced pleiotropic responses, including hepatic peroxisome proliferation and development of liver tumors.
The inability of synthetic peroxisome proliferators to interact with and damage DNA directly led to the proposal that sustained overproduction of H 2 O 2 and the resulting DNA damage due to disproportionate increases in H 2 O 2 -generating oxidases and H 2 O 2 -degrading enzyme catalase and liver cell proliferation contribute to liver tumor development in rodents (11, 12, 14, 16 -18) . While the consequences of sustained PPAR␣ activation, in particular the development of hepatocellular carcinomas, in species that manifest a profound degree of hepatic peroxisome proliferation are unequivocally established (2, 12, 17, 19) , it is argued that the carcinogenic risk to humans of chronic exposure to PPAR␣ ligands is negligible to nonexistent because human liver is assumed to be refractory to peroxisome proliferation (3, 19 -21) . This refractoriness of human hepatocytes to the inductive effects of PPAR␣ ligands, especially of peroxisome proliferation and induction of H 2 O 2 -generating peroxisomal ␤-oxidation system enzymes, is based primarily, if not exclusively, on data obtained with primary cultures of human hepatocytes and a human hepatocellular carcinoma cell line (21) (22) (23) . Many factors, such as low levels of PPAR␣ expression, expression of a human PPAR␣ splice variant that may negatively interfere with PPAR␣ function, differences in protein sequence between human and mouse PPAR␣, relative amounts of the three PPAR isotypes in liver cells, competition for the heterodimerization partner RXR, differences in the PPRE of target genes, and possible differences in nuclear receptor coactivators, may indeed account for the purported refractoriness of human hepatocytes to peroxisome proliferation (2, 3, 5, (21) (22) (23) (24) (25) (26) (27) (28) (29) .
The proposal that humans are resistant to induction of peroxisome proliferation and liver tumor development presupposes (i) that human liver cells in vivo are resistant to peroxisome proliferator-induced pleiotropic responses at the anticipated levels of exposure and (ii) that failure to observe a robust morphological phenomenon of peroxisome proliferative response signifies that changes in the expression patterns of other genes may not be relevant in the development of liver cancer. Widespread exposure to synthetic PPAR␣ ligands, nevertheless, raises a potential concern of carcinogenic risk to humans because of the uncertainty regarding the full spectrum of PPAR␣-regulated genes in liver and their role in liver cancer development (30) . Systematic analysis of molecular mechanisms underlying tissue and species-specific responses to PPAR␣ ligands requires examination of the role of various components of the transcriptional machinery (28, 29) and generation of molecular portraits of gene expression patterns (30) . In this study, we examined the functional competency of human PPAR␣ on the induction of PPAR␣ target genes in PPAR␣ Ϫ/Ϫ mouse liver to determine the role of the species origin of this receptor in peroxisome proliferator-induced immediate pleiotropic responses. Targeted disruption of PPAR␣ abolishes the induction of peroxisome proliferation and PPAR␣ target genes in mouse liver (10, 13) . We demonstrate that introduction of adenoviruses encoding human PPAR␣ or mouse PPAR␣ into PPAR␣ Ϫ/Ϫ mice fully restores the induction of ligand-mediated responses in liver. These studies establish that human PPAR␣ is functionally fully competent in inducing peroxisome proliferation within the context of mouse liver environment, and the human PPAR␣-mouse RXR chimeric heterodimer can transcriptionally activate mouse PPAR␣ target genes that contain the PPRE.
MATERIALS AND METHODS

Mice and Treatment with Peroxisome Proliferators-Wild type (C57BL/6J) mice and PPAR␣
Ϫ/Ϫ mice (13), 3-4 months of age and weighing 25-35 g, were used in this study. PPAR␣ Ϫ/Ϫ mice were maintained on powdered diet with or without Wy-14,643 (0.1% w/w), ciprofibrate (0.025% w/w), nafenopin (0.1% w/w), or di(2-ethylhexyl) phthalate (2% w/w) for 10 -14 days prior to adenovirus injection and killed on days 2, 3, 4, 5, or 6 after injection as indicated. For dose response of Ad/hPPAR␣ to Wy-14,643 the PPAR␣ Ϫ/Ϫ mice were maintained on powdered diet with different doses of Wy14,643 (0% w/w, 0.0125% w/w, 0.025% w/w, 0.05% w/w, and 0.1% w/w, respectively) from 1 day prior to injection and were killed 4 days later. For cell proliferation analysis, mice were given bromodeoxyuridine (0.5 mg/ml) in drinking water for 3 or 5 days after adenovirus injection, and their livers were processed for immunohistochemistry (31) . Animal procedures used in this study were approved by the Institutional Review Board for Animal Research of the Northwestern University.
Adenoviral Gene Transfer-Construction of recombinant adenovirus Ad/hPPAR␣ was as follows. Human PPAR␣ cDNA (32) was cloned into pCMV expression cassette at the SalI site, and the entire cassette was cut out with ClaI and BamHI and cloned into the EcoRV and BglII sites of pShuttle vector (Quantum Biotechnologies, Inc.). The linearized shuttle vector and AdEasy vector (Quantum Biotechnologies, Inc.) were then co-transformed into Escherichia coli strain BJ5183. Positive recombinant plasmid Ad/hPPAR␣ was selected (Fig. 1) . The linearized Ad/hPPAR␣ was then transfected with LipofectAMINE2000 (Life Technologies, Inc.) into the packaging cell HEK293A. Virus was purified with CsCl banding and stored at Ϫ70°C. The mouse PPAR␣ (mPPAR␣) cDNA (33) was cloned into pShuttle vector; the generation and manipulation of Ad/mPPAR␣ was as described for Ad/hPPAR␣. Adenoviral construct of Ad/LacZ was the generous gift of Dr W. El-Deiry (University of Pennsylvania, Philadelphia) and has been described previously (34) . Mice were intravenously injected (tail vein) in a volume of 200 l with 1 ϫ 10 11 virus particles of Ad/LacZ, Ad/hPPAR␣, or Ad/mPPAR␣. Mice injected with PBS served as controls. For dose response of Ad/ hPPAR␣ or Ad/mPPAR␣ to Wy-14,643 the PPAR␣ Ϫ/Ϫ mice were injected with 1 ϫ 10 11 virus particles of Ad/hPPAR␣ or Ad/mPPAR␣ as described above. Mice treated with 0.1% Wy14,643 and injected with PBS served as controls. Livers were separated and quickly fixed or frozen and used for the desired experiments.
Northern and Immunoblot Procedures-Total RNA was isolated from liver using Trizol reagent (Life Technologies, Inc.). After glyoxylation, samples were electrophoresed on an 0.8% agarose gel, transferred to a nylon membrane, and then hybridized at 42°C in a 50% formamide hybridization solution using 32 P-labeled cDNA probes as described previously (31) . Liver extracts were subjected to 7.5 or 10% SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and immunoblotted as described previously (10, 15, 31) . Some of the Western blot signals were quantified by scanning densitometry as previously described by using the NIH Image software (10, 31) . The values from PBS-injected mice were assigned the number 1.0.
Morphology-␤-Galactosidase activity was visualized by incubating liver sections in PBS containing 5 mM potassium ferricyanate, 2 mM MgCl 2 , and 1 ⁄20 volume of 20 mg/ml 5-bromo-4-chloro-3-indolyl ␤-Dgalactoside in dimethylformamide at 37°C. Tissue fixed in 10% neutral buffered formalin was embedded in paraffin using standard procedures. Sections (4-m thick) were cut and stained with hematoxylin and eosin. Immunohistochemical localization of human PPAR␣ (hPPAR␣), L-PBE, proliferating cell nuclear antigen, and bromodeoxyuridine was performed as described previously (31) . For cytochemical localization of peroxisomal catalase, tissues were fixed in 1.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 4 h at 4°C and incubated in alkaline 3Ј,3Ј-diaminobenzidine (DAB) substrate as described previously (14) . Semithin sections, without counterstain, were examined by light microscopy. Ultrathin sections for electron microscopy were contrasted with uranyl acetate and lead citrate.
RESULTS
General Approach-The availability of PPAR␣ Ϫ/Ϫ mice enabled us to determine the immediate effects of transient expression of human PPAR␣ on the induction of peroxisome proliferator-mediated pleiotropic responses in PPAR␣ Ϫ/Ϫ mouse hepatocytes in vivo. Since PPAR␣ Ϫ/Ϫ mice are nonresponsive to peroxisome proliferators, as they fail to manifest hepatic peroxisome proliferation and overexpression of genes regulated by PPAR␣ (10, 13), we used recombinant adenovirus to express human PPAR␣ in PPAR␣ Ϫ/Ϫ mouse liver and evaluated the immediate pleiotropic effects of PPAR␣ agonists. As expected, PPAR␣ Ϫ/Ϫ mice maintained on Wy-14,643-containing diet failed to show peroxisome proliferation and overexpression of PPAR␣ target genes in liver as evidenced by observations in mice given PBS or Ad/LacZ intravenously. To assess the ability of adenovirally expressed recombinant human PPAR␣ to support peroxisome proliferation in PPAR␣ Ϫ/Ϫ mouse hepatocytes, we infected PPAR␣ Ϫ/Ϫ mice maintained on a diet containing Wy-14,643 with 6.125 ϫ 10 9 -4 ϫ 10 11 infectious viral particles by tail vein injection and determined the expression levels of L-PBE, the second enzyme of the inducible classical peroxisomal ␤-oxidation system (1). Immunoblots of liver samples obtained 4 days after infection revealed maximum induction with 1 ϫ 10 11 infectious viral particles ( Fig. 2A) . At the higher viral load (4 ϫ 10 11 ), no further increase in L-PBE expression was noted despite increased expression of human PPAR␣. Peroxisomal catalase level did not change in these livers after Ad/ hPPAR␣ ( Fig. 2A) as this gene is not regulated by PPAR␣ (12) . To investigate the time period between recombinant viral infection and the induction of human PPAR␣ to effectuate induction of PPAR␣-responsive genes in PPAR␣ Ϫ/Ϫ liver, mice were killed at 2, 3, 4, 5, and 6 days after a single tail vein injection of 1 ϫ 10 11 viral particles. As illustrated in Fig. 2B , hPPAR␣ was barely detectable until day 3, although the expression of L-PBE began to manifest on day 2, suggesting that PPAR␣ target genes are transcriptionally activated as soon as the expression of this receptor ensues. After day 3, the L-PBE levels increased perceptibly with maximum expression between 4 and 6 days (Fig. 2B) . PPAR␣ Ϫ/Ϫ mice that did not receive Wy-14,643 failed to show L-PBE induction when infected with Ad/mPPAR␣ (Fig. 2C, lane 2) or Ad/hPPAR␣ (Fig.  2C, lane 7) suggesting that the natural/biological ligands are insufficient to activate the introduced mPPAR␣ or hPPAR␣ as these ligands can be effectively metabolized by the peroxisomal AOX (14, 18) . We determined the dose response to ascertain the comparative sensitivity of normalized expression of human and mouse PPAR␣ in PPAR-null liver to Wy-14,643 (Fig. 2, C and  D) . The data indicate that both mouse and human PPAR␣ respond similarly to a given dose of Wy-14,643 as determined by the expression of L-PBE.
Human PPAR␣-directed Induction of Peroxisome Proliferation in PPAR␣
Ϫ/Ϫ Mouse Liver-To fully evaluate the effect of human PPAR␣ in the PPAR␣-null mouse liver, we injected 1 ϫ 10 11 viral particles intravenously and analyzed livers of mice killed on days 4 and 6 after infection for peroxisome proliferation and peroxisome proliferator-induced immediate pleiotropic responses (Figs. 3 and 4) . Nearly 60% of hepatocytes stained 11 Ad/hPPAR␣ viral particles and killed 2, 3, 4, 5, and 6 days after infection. PPAR␣ Ϫ/Ϫ mice injected with PBS or Ad/LacZ were killed 6 days after the injection. Liver samples were immunoblotted for PPAR␣, L-PBE, and catalase. C and D, dose-response studies in PPAR␣-null mice expressing the same amount of human or mouse PPAR␣ in liver. Wy-14,643 was administered in the diet at the concentrations indicated, and mice were injected with the same amount of mouse (lanes 2-6) or human (lanes 7-11) adenoviral particles containing PPAR␣ (1 ϫ 10 11 ). Lanes 2 and 7 represent mouse and human controls, respectively. Lane 1 represents PPAR-null mouse given PBS and no PPAR-containing virus while maintained on Wy-14,643, and the values are used as a baseline for comparison (black box). PPAR␣-injected mice given PBS and no drug were used to assess the effect if any of endogenous ligands. L-PBE and catalase expression in liver was determined by immunoblot analysis (C), and the data was quantitated (D). ‚ and Ⅺ represent L-PBE levels obtained with mouse and human PPAR, respectively. ϫ and q represent catalase levels obtained with mouse and human receptor, respectively. d, days.
positively for ␤-galactosidase activity in PPAR␣ Ϫ/Ϫ mice injected with Ad/LacZ and killed 4 or 6 days after injection (Fig.  3A) . Likewise ϳ60 -70% of hepatocytes expressed hPPAR␣ transgene at immunohistochemically detectable levels between 4 and 6 days postinjection (Fig. 3B) . As expected, control PPAR␣ Ϫ/Ϫ livers revealed no PPAR␣ expression (Figs. 2, 3C , and 4). No significant inflammatory infiltrate was detected in any of the livers infected with Ad/hPPAR␣ during the 6-day duration of this study. Hepatic peroxisome proliferation in PPAR␣ Ϫ/Ϫ mice that were fed either control diet or Wy-14,643-containing diet and infected with Ad/hPPAR␣ transgene was evaluated by immunohistochemical staining for L-PBE (Fig. 3,  D and E) . Intense granular staining of hepatocyte cytoplasm was evident in Wy-14,643-fed PPAR␣ Ϫ/Ϫ mice expressing human PPAR␣ transgene (Fig. 3D ) when compared with PPAR␣ Ϫ/Ϫ mice maintained on Wy-14,643 but given PBS or Ad/LacZ intravenously (Fig. 3E) . PPAR␣ Ϫ/Ϫ mice that were injected with Ad/hPPAR␣ but maintained on normal chow without the ligand failed to show peroxisome proliferation (not illustrated). Peroxisome proliferation was also evaluated by light microscopic (Fig. 3, F and G) and electron microscopic (not illustrated) evaluation of sections of liver processed to visualize peroxisomal catalase. Marked increases in the number and size of peroxisomes in the liver of the Wy-14,643-fed PPAR␣ Ϫ/Ϫ mouse were clearly seen 6 days after Ad/hPPAR␣ infection (Fig. 3F) as compared with the control PPAR␣ Ϫ/Ϫ mouse (Fig.  3G) . Liver cell proliferation, as assessed by bromodeoxyuridine incorporation or by staining for proliferating cell nuclear antigen in Wy-14,643-fed PPAR␣ Ϫ/Ϫ mice 5 days after Ad/hPPAR␣ (Fig. 3H) or Ad/LacZ (Fig. 3I ) infection, was not significantly different from that observed in Wy-14,643-treated wild type mice (Fig. 3J) , implying that human PPAR␣ can support the initial wave of liver cell proliferation occurring after exposure to peroxisome proliferators (35) . These observations clearly establish that the presence of exogenous synthetic ligand alone in the PPAR␣ Ϫ/Ϫ liver cells or the expression of exogenous human PPAR␣ in the absence of synthetic PPAR␣ ligand such as Wy-14,643 is not sufficient to induce peroxisome proliferation and liver cell proliferation.
Human PPAR␣-directed Gene Expression in PPAR␣ Ϫ/Ϫ
Mouse Liver-To investigate whether human PPAR␣ is sufficient for the mediation of peroxisome proliferator-induced immediate pleiotropic responses in PPAR␣ Ϫ/Ϫ mouse liver, we evaluated the mRNA levels of several well known PPAR␣-regulated genes such as AOX, L-PBE, peroxisomal 3-ketoacylCoA thiolase, CYP4A1, and CYP4A3 by Northern blotting (Fig.  4A) . As expected, administering Wy-14,643 to PPAR␣ Ϫ/Ϫ mice failed to induce overexpression of PPAR␣-regulated genes (see Ad/LacZ and PBS groups). When human PPAR␣ transgene was introduced by adenoviral approach, a marked overexpression of target gene mRNAs was discerned in Wy-14,643-fed PPAR␣ Ϫ/Ϫ mouse livers 4 and 6 days postinjection (Fig. 4A ). In the absence of ligand, human PPAR␣ transgene failed to induce overexpression of these target genes (data not shown). We also evaluated the induction of fatty acid-metabolizing enzymes in the liver of PPAR␣ Ϫ/Ϫ mice expressing human PPAR␣ by immunoblotting (Fig. 4, B and C) . Levels of hepatic peroxisomal fatty acid ␤-oxidation enzymes in the Wy-14,643-treated PPAR␣ Ϫ/Ϫ mouse liver were similar to the constitutive levels of expression as reported previously (10, 13) , but the human PPAR␣-expressing PPAR␣ Ϫ/Ϫ mouse livers exhibited significant increases in Wy-14,643-mediated AOX, L-PBE, and peroxisomal 3-ketoacyl-CoA thiolase (Fig. 4B) . A modest increase in very long chain acyl-CoA dehydrogenase and medium chain acyl-CoA dehydrogenase, the enzymes involved in mitochondrial lipid metabolism, was noted (Fig. 4B) . Hepatic levels of catalase and urate oxidase, two peroxisomal enzymes not known to be regulated by PPAR␣, did not change in Wy-14,643-treated PPAR␣ Ϫ/Ϫ mice irrespective of the PPAR␣ status. Recently, using cDNA microarray, we identified several genes that are up-regulated in the Wy-14,643-treated wild type mouse liver, and none of these encode peroxisomal proteins (30) . These include CD36, monoglyceride lipase, Ly-6D, cell death-inducing DNA fragmentation factor ␣, pyruvate dehydrogenase kinase-4, C3f, and others (27) . Up-regulation of these genes in mouse liver was shown to be dependent upon peroxisome proliferation vis à vis PPAR␣ as no induction was noted in PPAR␣ Ϫ/Ϫ mice treated with peroxisome proliferators (27) . To determine whether human PPAR␣ can also mediate the expression of these newly identified genes we assessed the levels of expression of six genes, namely CD36, Ly-6D, Rbp7, monoglyceride lipase, C3f, and pyruvate dehydrogenase kinase-4, in Wy-14,643-treated PPAR␣ Ϫ/Ϫ mouse liver expressing human PPAR␣ (Fig. 5) . Human PPAR␣ expression resulted in the up-regulation of these genes in Wy-14,643-treated PPAR␣ Ϫ/Ϫ mouse liver (Fig. 5) , indicating that human PPAR␣ is also capable of regulating these genes in livers in response to synthetic PPAR␣ ligands.
Comparative Response of Human and Mouse PPAR␣ to Structurally Different Peroxisome Proliferators-We sought to assess the comparative ability of ciprofibrate, di(2-ethylhexyl) phthalate, nafenopin, and Wy-14,643 to activate human and mouse PPAR␣ in PPAR␣ Ϫ/Ϫ mice. PPAR␣ Ϫ/Ϫ mice were fed a diet containing one of these peroxisome proliferators, and the expressions of three PPAR␣ target genes (AOX, L-PBE, and CYP4A3) in liver was analyzed 4 days after intravenous injection of 1 ϫ 10 11 particles of Ad/hPPAR␣, Ad/mPPAR␣, or Ad/ LacZ (Fig. 6A) . In Northern blots, under the hybridization conditions used, hPPAR␣ did not recognize mPPAR␣; likewise the mPPAR cDNA probe failed to recognize hPPAR␣ (Fig. 6A) . All four peroxisome proliferators used in this experiment activated both human and mouse PPAR␣ in a qualitatively similar manner as evidenced by the levels of mRNA expression of target genes (Fig. 6A) . The catalase mRNA level in liver served as a loading control in all groups. We also assessed the constitutive and inducible levels of AOX and L-PBE by immunoblot analysis (Fig. 6, B and C) . Both human and mouse PPAR␣ caused marked increases in the protein content of AOX as well as L-PBE, the first two enzymes of the inducible peroxisomal ␤-oxidation system in PPAR␣ Ϫ/Ϫ mouse liver in response to structurally different PPAR␣ ligands.
DISCUSSION
Several nuclear receptors such as PPAR␣ (4), Ahr (36), constitutive androstane receptor (37, 38) , and steroid and xenobiotic receptor/pregnenolone X receptor (39) regulate the tran- scriptional activation of specific target genes in liver in response to xenobiotic ligands. Inducible gene expression, resulting from exposure to xenobiotic chemicals that transcriptionally activate genes by a receptor-mediated mechanism, presents many uncertainties when extrapolating the toxicological implications from one species to the other and in assessing risk to humans. Evidence suggests that some of these receptors function as species-specific xenosensors (39) , and they may differ in their content or protein composition to account for species differences in the expected responses (24) . Species differences in the magnitude of xenobiotic-induced hepatic peroxisome proliferation, especially between rodents and humans, are documented, but the mechanisms remain largely speculative. A close concordance with the magnitude of peroxisome proliferation and hepatocarcinogenesis in rats and mice (2, 3, 19) is used as the basis for the assertion that since humans appear to be refractory to hepatic peroxisome proliferation they are resistant to the inductive effects of PPAR␣ ligands including liver cancer risk (19 -21) . Humans possess a functional PPAR␣, but it is has been shown to be weaker in response to Wy-14,643 when compared with that of rat and mouse PPAR␣s in trans-activation assays (6, 24, 25, 27, 32) . The low levels of PPAR␣ expression in human liver and the presence of PPAR␣ splice variants have also been suggested to contribute to the resistance of human hepatocytes to peroxisome proliferation (22) (23) (24) (25) . Increasing the expression of PPAR␣ in HepG2 cells to levels found in mouse liver has not been found sufficient to confer peroxisome proliferator-induced responsiveness (22, 23) . These results imply that HepG2 cell lines may have acquired many epigenetic alterations, such as methylation of genes, in passage over the years as they also lack expression of CYP4A11 and possibly other genes. These considerations as well as differences in the levels of PPAR␣ and its heterodimerization partner RXR and in the PPRE of target genes or other components of transcriptional machinery may contribute to the nonresponsiveness of human hepatocytes (28, 29, 40) . The assumption that human AOX and possibly the entire panoply of peroxisomal ␤-oxidation system genes and CYP4A -oxidation genes in human have evolutionarily been altered appears somewhat farfetched and is not based on sound rationale (23, 41) . Human PPAR␣ has been found to differ at some amino acid positions in the ligand binding domain from rat and mouse receptor (27, 32) , but the pharmacological relevance of these changes has not been established. The data we present in this study on the response to different ligands and to varying doses of Wy-14,643 suggest that these differences do not alter the sensitivity of the human PPAR␣.
Our results clearly show that human PPAR␣ is fully capable of transcriptionally activating peroxisomal ␤-oxidation system genes as well as several nonperoxisomal genes, and this receptor is as effective as mouse PPAR␣ under in vivo conditions within the context of intact liver. These studies demonstrate the restoration of peroxisome proliferator-induced pleiotropic responses in PPAR␣ Ϫ/Ϫ mouse liver with recombinant adenovirus that expresses human PPAR␣ or mouse PPAR␣. In the absence of exogenous ligands, the mouse or human PPAR␣ failed to elicit significant alterations in the expression of PPAR␣ target genes (Fig. 2C, lanes 2 and 7) , implying that the endogenous ligands such as very long chain fatty acids and/or their acyl-CoAs do not exert any inductive effects as these are effectively metabolized by AOX (1, 14) . Human PPAR␣ activated a full spectrum of target genes in mouse liver, and these include many well characterized genes such as AOX, L-PBE, peroxisomal 3-ketoacyl-CoA thiolase, CYP4A1, and CYP4A3 that possess PPREs in their 5Ј-flanking regions (2, 4). The overexpression of these genes in PPAR␣ Ϫ/Ϫ liver with human PPAR␣ establishes that human PPAR␣ heterodimerizes with mouse RXR in mouse liver in vivo, and the chimeric hPPAR␣-mRXR heterodimers recognize the PPRE in mouse target genes. Also of interest is that hPPAR␣ in PPAR␣ Ϫ/Ϫ mouse liver enhanced the expression of several newly identified genes found to be overexpressed in mouse liver with peroxisome proliferation in a PPAR␣-dependent fashion (30) . These include CD36 (42), Ly-6D (43), pyruvate dehydrogenase kinase-4 (44), monoglyceride lipase (45), Rbp7 (46) , and C3f (47) . CD36 and Ly-6D are cell surface/membrane-associated proteins whose functions in peroxisome proliferator-induced pleiotropic responses remain to be explored. CD36, a scavenger receptor known to interact with a large variety of ligands including oxidized low density lipoproteins, is up-regulated in Wy-14,643-treated mouse livers with peroxisome proliferation (48) and has been shown to play a role in foam cell conversion of macrophages (48) . Because of the induction in liver of many nonperoxisomal genes by synthetic PPAR␣ ligands and since hPPAR␣ is functionally capable of mediating this induction, we consider the assumption that human liver cells are refractory to the induction of peroxisome proliferator-induced pleiotropic responses including liver cancer development somewhat premature.
For many xenobiotics, there is no reliable system other than in humans to assess the toxicological significance directly and quantitatively (39) . Recently a "humanized" animal to establish the role of steroid and xenobiotic receptor/pregnenolone X receptor activation in xenoprotection was developed to demonstrate that species origin of the receptor, rather than the promoter structure of CYP3A genes, dictates the species-specific pattern of CYP3A inducibility (39) . The adenoviral-controlled expression of human PPAR␣ provided valuable information on the ability of this receptor to support peroxisome proliferatorinduced immediate pleiotropic responses, but this approach cannot be used for long term studies or for effective quantitative titration of hPPAR␣ expression that is identical to the mPPAR␣ normally expressed in mouse liver so that extrapolation of risk between rodents and humans can be made as to the relative levels of PPAR␣ expressed in these susceptible and resistant species. Development of humanized PPAR␣ Ϫ/Ϫ mouse strains that express different levels of human PPAR␣ under the control of the albumin promoter in liver will be useful for such comparison and also for long term carcinogenic studies. More importantly, mouse liver repopulated with human hepatocytes (49) may prove to be immensely informative to evaluate the immediate and delayed pleiotropic responses induced by PPAR␣ ligands in intact human liver cells.
